GAITHERSBURG, Md., June 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today a number of promotions within its management team.
John A. Herrmann III, J.D. has been named Senior Vice President, General Counsel and Corporate Secretary. Mr. Herrmann joined Novavax in March 2010 and is responsible for managing all of Novavax' legal affairs, including its patent portfolio, transactional and contractual matters, public securities filings, and attending to all the duties of Corporate Secretary. Mr. Herrmann also works with the company's senior management team to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann served as General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Prior to joining Gene Logic, Mr. Herrmann served as Senior Counsel for Celera Genomics and prior to that as Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann received his B.A. in Political Science and History from Brown University and his J.D. from the University of Illinois.
Denise Courbron, M.S., PMP has been named Vice President, Global Program Management to lead Novavax' program management efforts covering all vaccine development programs. Ms. Courbron joined Novavax in June 2010 as Executive Director, Global Program Management and was instrumental in Novavax' being awarded its $179 million influenza development contract with HHS BARDA in February 2011. Prior to joining Novavax, Ms. Courbron held positions of increasing responsibility in a number of companies in the vaccines industry, including PharmAthene, Intercell USA, Iomai Corporation, PPD, Baxter BioScience, GloboMax (ICON), and North American Vaccine. Ms. Courbron received a B.A. in Political Science and Spanish from Western Maryland College (McDaniel) and an M.S. in Biotechnology Management from the University of Maryland University College. Ms. Courbron is a certified Project Management Professional (PMPTM).
"I am very pleased to announce the promotions of John and Denise. Their contributions over the last number of years have been critical to the success of the company. John has been irreplaceable assisting the management team and the board to navigate the regulatory, compliance, and corporate governance requirements of a public company. Denise's long history of experience with government contracts and project management has been integral to the successful execution of our contract with HHS BARDA. I look forward to their continued involvement in the success of the company," said Stanley C. Erck, President and CEO.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000